## Samreen Ijaz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/793597/publications.pdf

Version: 2024-02-01

45213 50170 8,703 128 46 90 citations h-index g-index papers 132 132 132 7655 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Bloodâ€borne virus testing in emergency departments – a systematic review of seroprevalence, feasibility, acceptability and linkage to care. HIV Medicine, 2023, 24, 6-26.	1.0	5
2	Mother to Infant Transmission of Hepatitis B Virus in the Face of Neonatal Immunization Is Not Necessarily Primary Vaccine Failure. Clinical Infectious Diseases, 2022, 74, 1151-1157.	2.9	1
3	Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility. Journal of Virological Methods, 2022, 302, 114475.	1.0	8
4	Simple, sensitive, specific self-sampling assay secures SARS-CoV-2 antibody signals in sero-prevalence and post-vaccine studies. Scientific Reports, 2022, 12, 1885.	1.6	3
5	Epidemiology of HIV infection and associated behaviours among people who inject drugs in England, Wales, and Northern Ireland: Nearly 40Âyears on. HIV Medicine, 2022, 23, 978-989.	1.0	5
6	The COVID-19 Schools Infection Survey in England: Protocol and Participation Profile for a Prospective Observational Cohort Study. JMIR Research Protocols, 2022, 11, e34075.	0.5	6
7	Mapping of SARS-CoV-2 IgM and IgG in gingival crevicular fluid: Antibody dynamics and linkage to severity of COVID-19 in hospital inpatients. Journal of Infection, 2022, 85, 152-160.	1.7	6
8	Persistent Hepatitis E virus infection across England and Wales 2009â€2017: Demography, virology and outcomes. Journal of Viral Hepatitis, 2021, 28, 420-430.	1.0	12
9	Impact of a nurseâ€led enhanced monitoring, management and contact tracing intervention for chronic hepatitis B in England, 2015â€2017. Journal of Viral Hepatitis, 2021, 28, 72-79.	1.0	6
10	Convalescent plasma therapy for the treatment of patients with COVIDâ€19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. Transfusion Medicine, 2021, 31, 167-175.	0.5	71
11	Ebola virus antibody decay–stimulation in a high proportion of survivors. Nature, 2021, 590, 468-472.	13.7	30
12	Boosting understanding of Lassa Fever virus epidemiology: Field testing a novel assay to identify past Lassa Fever virus infection in blood and oral fluids of survivors and unexposed controls in Sierra Leone. PLoS Neglected Tropical Diseases, 2021, 15, e0009255.	1.3	0
13	Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respiratory Medicine,the, 2021, 9, 699-711.	5.2	122
14	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. Lancet Respiratory Medicine, the, 2021, 9, 349-359.	5.2	161
15	Case–Control Study of Risk Factors for Acquired Hepatitis E Virus Infections in Blood Donors, United Kingdom, 2018–2019. Emerging Infectious Diseases, 2021, 27, 1654-1661.	2.0	8
16	Prevalence of hepatitis B immunity and infection in home self-sampling HIV service users. Sexually Transmitted Infections, 2021, , sextrans-2021-055071.	0.8	3
17	Hepatitis E virus: Whole genome sequencing as a new tool for understanding HEV epidemiology and phenotypes. Journal of Clinical Virology, 2021, 139, 104738.	1.6	3
18	Hepatitis B infections among blood donors in <scp>England</scp> between 2009 and 2018: Is an occult hepatitis B infection a risk for blood safety?. Transfusion, 2021, 61, 2402-2413.	0.8	19

#	Article	IF	Citations
19	Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. Lancet Respiratory Medicine, the, 2021, 9, 773-785.	5.2	78
20	Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. Lancet, The, 2021, 398, 223-237.	6.3	110
21	The impact of directâ€acting antivirals on hepatitis C viraemia among people who inject drugs in England; realâ€world data 2011–2018. Journal of Viral Hepatitis, 2021, 28, 1452-1463.	1.0	10
22	Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. Lancet Rheumatology, The, 2021, 3, e498-e506.	2.2	58
23	Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. Lancet Microbe, The, 2021, 2, e354-e365.	3.4	216
24	A prenylated dsRNA sensor protects against severe COVID-19. Science, 2021, 374, eabj3624.	6.0	124
25	Transmission of SARS-CoV-2 in the household setting: A prospective cohort study in children and adults in England. Journal of Infection, 2021, 83, 483-489.	1.7	37
26	Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020. Eurosurveillance, 2020, 25, .	3.9	53
27	Absence of Persistent Hepatitis E Virus Infection in Antibody-Deficient Patients Is Associated With Transfer of Antigen-Neutralizing Antibodies From Immunoglobulin Products. Journal of Infectious Diseases, 2019, 219, 245-253.	1.9	7
28	Modulated Zika virus NS1 conjugate offers advantages for accurate detection of Zika virus specific antibody in double antigen binding and Ig capture enzyme immunoassays. PLoS ONE, 2019, 14, e0215708.	1.1	6
29	Hepatitis E virus in blood donors in England, 2016 to 2017: from selective to universal screening. Eurosurveillance, 2019, 24, .	3.9	40
30	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) – a natural experiment (protocol). BMJ Open, 2019, 9, e029538.	0.8	30
31	Standardising surveillance of hepatitis E virus infection in the EU/EEA: A review of national practices and suggestions for the way forward. Journal of Clinical Virology, 2019, 120, 63-67.	1.6	14
32	Convalescent plasma therapy for persistent hepatitis E virus infection. Journal of Hepatology, 2019, 71, 434-438.	1.8	17
33	Epidemiology of Hepatitis E in England and Wales: A 10-Year Retrospective Surveillance Study, 2008–2017. Journal of Infectious Diseases, 2019, 220, 802-810.	1.9	19
34	Causes of death among persons diagnosed with hepatitis C infection in the pre―and postâ€ĐAA era in England: A record linkage study. Journal of Viral Hepatitis, 2019, 26, 873-880.	1.0	12
35	Characterising the risk of Hepatitis E virus infection in haematological malignancies: a <scp>UK</scp> prospective prevalence study. British Journal of Haematology, 2019, 186, 191-195.	1.2	8
36	Response to: â€~Chronic genotype 1 hepatitis E infection from immunosuppression for ileo-colonic Crohn's disease'. Oxford Medical Case Reports, 2019, 2019, omy125.	0.2	4

#	Article	IF	CITATIONS
37	Noninvasive Detection of Antibodies to Human T-Cell Lymphotropic Virus Types $1\ \rm and\ 2$ by Use of Oral Fluid. Journal of Clinical Microbiology, 2019, 57, .	1.8	5
38	Wide spectrum of referral routes for acute hepatitis E infections. Journal of Infection, 2019, 78, 249-259.	1.7	0
39	Resolution by deep sequencing of a dual hepatitis E virus infection transmitted via blood components. Journal of General Virology, 2019, 100, 1491-1500.	1.3	5
40	Toward Systematic Screening for Persistent Hepatitis E Virus Infections in Transplant Patients. Transplantation, 2018, 102, 1139-1147.	0.5	27
41	Hepatitis B Virus Immunization and Neonatal Acquisition of Persistent Infection in England and Wales. Journal of Infectious Diseases, 2018, 218, 726-733.	1.9	7
42	Establishing the cascade of care for hepatitis C in Englandâ€"benchmarking to monitor impact of direct acting antivirals. Journal of Viral Hepatitis, 2018, 25, 482-490.	1.0	23
43	Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone. Transfusion, 2018, 58, 1289-1298.	0.8	23
44	Confirmation of specificity of reactivity in a solid phase ELISA for the detection of hepatitis E viral antigen improves utility of the assay. Journal of Virological Methods, 2018, 252, 42-48.	1.0	7
45	Summary of the British Transplantation Society UK Guidelines for Hepatitis E and Solid Organ Transplantation. Transplantation, 2018, 102, 15-20.	0.5	58
46	Hepatitis E infection in stem cell and solid organ transplantpatients: A cross-sectional study. Journal of Clinical Virology, 2018, 107, 1-5.	1.6	18
47	A comparison of two biological markers of recent hepatitis C virus (HCV) infection: implications for the monitoring of interventions and strategies to reduce HCV transmission among people who inject drugs. Eurosurveillance, 2018, 23, .	3.9	8
48	Hepatitis E risks: pigs or bloodâ€"that is the question. Transfusion, 2017, 57, 267-272.	0.8	66
49	Racial differences in seroprevalence of HAV and HEV in blood donors in the Western Cape, South Africa: a clue to the predominant HEV genotype?. Epidemiology and Infection, 2017, 145, 1910-1912.	1.0	12
50	Antibody-based assay discriminates Zika virus infection from other flaviviruses. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 8384-8389.	3.3	161
51	Pork products associated with human infection caused by an emerging phylotype of hepatitis E virus in England and Wales. Epidemiology and Infection, 2017, 145, 2417-2423.	1.0	28
52	Stage of disease in hepatitis B virus infection in Zambian adults is associated with large cell change but not well defined using classic biomarkers. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2017, 111, 425-432.	0.7	3
53	Acute Hepatitis E Mimicking a Flare of Disease in a Patient with Chronic Autoimmune Hepatitis. Annals of Hepatology, 2017, 16, 160-163.	0.6	8
54	Hepatitis E virus infection in Europe: surveillance and descriptive epidemiology of confirmed cases, 2005 to 2015. Eurosurveillance, 2017, 22, .	3.9	127

#	Article	IF	CITATIONS
55	Hepatitis E virus infection in the Irish blood donor population. Transfusion, 2016, 56, 2868-2876.	0.8	52
56	Hepatitis E virus: Assessment of the epidemiological situation in humans in Europe, 2014/15. Journal of Clinical Virology, 2016, 82, 9-16.	1.6	168
57	Virology, serology, and demography of hepatitis E viremic blood donors in South East England. Transfusion, 2016, 56, 1529-1536.	0.8	38
58	An outbreak of hepatitis B in men who have sex with men but identify as heterosexual. Sexually Transmitted Infections, 2016, 92, 227-227.	0.8	10
59	Liver transplantation for acute liver failure because of genotype 3 hepatitis E virus infection. Liver Transplantation, 2015, 21, 1557-1559.	1.3	8
60	Prevalence of Hepatitis E Virus Infection in Pigs at the Time of Slaughter, United Kingdom, 2013. Emerging Infectious Diseases, 2015, 21, 1396-1401.	2.0	88
61	Transverse myelitis caused by hepatitis E: previously undescribed in adults. BMJ Case Reports, 2015, 2015, bcr2014209031.	0.2	9
62	Molecular epidemiology of newly acquired hepatitis C infections in England 2008–2011: Genotype, phylogeny and mutation analysis. Journal of Clinical Virology, 2015, 64, 6-11.	1.6	9
63	Variability and pathogenicity of hepatitis E virus genotype 3 variants. Journal of General Virology, 2015, 96, 3255-3264.	1.3	54
64	Seroepidemiology of Hepatitis E Virus Infection in an Urban Population in Zambia: Strong Association With HIV and Environmental Enteropathy. Journal of Infectious Diseases, 2014, 209, 652-657.	1.9	31
65	Acute hepatitis B in blood donors over a 5-year period in England and North Wales: who is getting infected?. Transfusion, 2014, 54, 1660-1665.	0.8	3
66	Hepatitis E Infection in a Renal Transplant Recipient. Case Reports in Nephrology, 2014, 2014, 1-4.	0.2	1
67	Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet, The, 2014, 384, 1766-1773.	6.3	466
68	Indigenous Hepatitis E in England and Wales From 2003 to 2012: Evidence of an Emerging Novel Phylotype of Viruses. Journal of Infectious Diseases, 2014, 209, 1212-1218.	1.9	106
69	Hepatitis E virus in England and Wales: indigenous infection is associated with the consumption of processed pork products. Epidemiology and Infection, 2014, 142, 1467-1475.	1.0	94
70	The diversity of chronic hepatitis <scp>B</scp> virus infections within blood donors in <scp>E</scp> ngland and <scp>N</scp> orth <scp>W</scp> ales 2005 through 2010. Transfusion, 2013, 53, 2467-2476.	0.8	8
71	A re-assessment of the epidemiology and patient characteristics of hepatitis D virus infection in inner city London. Journal of Infection, 2013, 66, 521-527.	1.7	19
72	Chronic Hepatitis E as a cause for cryptogenic cirrhosis in HIV. Journal of Infection, 2013, 66, 103-106.	1.7	81

#	Article	IF	Citations
73	Immune reconstitution hepatitis E. Aids, 2013, 27, 487-489.	1.0	20
74	Hepatitis E Virus Seroprevalence among Men Who Have Sex with Men, United Kingdom. Emerging Infectious Diseases, 2013, 19, 333-336.	2.0	36
75	The Diversity and Management of Chronic Hepatitis B Virus Infections in the United Kingdom: A Wake-up Call. Clinical Infectious Diseases, 2013, 56, 951-960.	2.9	35
76	The †Red Queen' dilemma – running to stay in the same place: reflections on the evolutionary vector of HBV in humans. Antiviral Therapy, 2013, 18, 489-496.	0.6	24
77	Hepatitis E virus coinfection in patients with HIV infection. HIV Medicine, 2012, 13, 83-88.	1.0	75
78	High HBV Viral Loads in HIV-Infected Pregnant Women at a Tertiary Hospital, South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, e111-e112.	0.9	19
79	Hepatitis E. Lancet, The, 2012, 379, 2477-2488.	6.3	805
80	Molecular epidemiology of a large community-based outbreak of hepatitis B in Bristol, UK. Journal of Clinical Virology, 2012, 53, 125-129.	1.6	8
81	Minor groove binder modification of widely used TaqMan probe for hepatitis E virus reduces risk of false negative real-time PCR results. Journal of Virological Methods, 2012, 186, 157-160.	1.0	101
82	Detection of hepatitis E virus RNA in plasma miniâ€pools from blood donors in England. Vox Sanguinis, 2012, 102, 272-272.	0.7	70
83	Investigating the impact of hepatitis B virus surface gene polymorphism on antigenicity using ex vivo phenotyping. Journal of General Virology, 2012, 93, 2473-2479.	1.3	13
84	Five hepatitis B outbreaks in care homes in the UK associated with deficiencies in infection control practice in blood glucose monitoring. Epidemiology and Infection, 2011, 139, 327-335.	1.0	24
85	Treatment of Chronic Hepatitis E in a Patient With HIV Infection. Annals of Internal Medicine, 2011, 155, 479.	2.0	103
86	Is there evidence of recent hepatitis E virus infection in English and North Welsh blood donors?. Vox Sanguinis, 2011, 100, 340-342.	0.7	88
87	Hepatitis E Virus and Neurologic Disorders. Emerging Infectious Diseases, 2011, 17, 173-179.	2.0	279
88	Hepatitis B transmission event in an English prison and the importance of immunization. Journal of Public Health, 2011, 33, 193-196.	1.0	8
89	Diagnostic Strategy Used To Establish Etiologies of Encephalitis in a Prospective Cohort of Patients in England. Journal of Clinical Microbiology, 2011, 49, 3576-3583.	1.8	65
90	Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells. Hepatology, 2010, 52, 875-885.	3.6	63

#	Article	IF	Citations
91	A comparison of two commercially available antiâ∈HEV IgG kits and a reâ∈evaluation of antiâ∈HEV IgG seroprevalence data in developed countries. Journal of Medical Virology, 2010, 82, 799-805.	2.5	282
92	The genetic backbone modulates the phenotype of hepatitis B surface antigen mutants. Journal of General Virology, 2010, 91, 68-73.	1.3	10
93	First case of genotype 4 human hepatitis E virus infection acquired in India. Journal of Clinical Virology, 2010, 48, 58-61.	1.6	33
94	Hepatitis E Outbreak on Cruise Ship. Emerging Infectious Diseases, 2009, 15, 1738-1744.	2.0	224
95	Persistent Carriage of Hepatitis E Virus in Patients with HIV Infection. New England Journal of Medicine, 2009, 361, 1025-1027.	13.9	496
96	Indigenous hepatitis E virus infection in England: More common than it seems. Journal of Clinical Virology, 2009, 44, 272-276.	1.6	120
97	Hepatitis B virus reactivation in a large haemodialysis unit: Virological and infection control issues. Journal of Clinical Virology, 2009, 46, 101-103.	1.6	2
98	Autochthonous hepatitis E in Southwest England: a comparison with hepatitis A. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 579-585.	1.3	57
99	Serological response to hepatitis E virus genotype 3 infection: IgG quantitation, avidity, and IgM response. Journal of Medical Virology, 2008, 80, 95-101.	2.5	88
100	Dynamics of lamivudineâ€resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. Journal of Medical Virology, 2008, 80, 1160-1170.	2.5	44
101	Of pigs and pregnancy. Lancet, The, 2008, 372, 1192.	6.3	25
102	Hepatitis E: an emerging infection in developed countries. Lancet Infectious Diseases, The, 2008, 8, 698-709.	4.6	601
103	Hepatitis E autochthonous infection in chronic liver disease. European Journal of Gastroenterology and Hepatology, 2008, 20, 800-803.	0.8	32
104	Autochthonous hepatitis E in Southwest England: natural history, complications and seasonal variation, and hepatitis E virus IgG seroprevalence in blood donors, the elderly and patients with chronic liver disease. European Journal of Gastroenterology and Hepatology, 2008, 20, 784-790.	0.8	255
105	Hepatitis E in England and Wales. Emerging Infectious Diseases, 2008, 14, 165-167.	2.0	65
106	Correlation between hepatitis B genotypes, 1896 precore mutation, virus loads and liver dysfunction in an Indian population. Indian Journal of Gastroenterology, 2008, 27, 142-7.	0.7	6
107	Antiviral Resistance Mutations Potentiate hepatitis B virus Immune Evasion through Disruption of its Surface Antigen <i>a</i> Determinant. Antiviral Therapy, 2008, 13, 439-448.	0.6	49
108	HepSEQ: International Public Health Repository for Hepatitis B. Nucleic Acids Research, 2007, 35, D367-D370.	6.5	16

#	Article	IF	CITATIONS
109	Passage from India: an outbreak of hepatitis B linked to a patient who acquired infection from health care overseas. Public Health, 2007, 121, 734-741.	1.4	27
110	Transmission of hepatitis B virus (genotype E) in a haemodialysis unit. Journal of Clinical Virology, 2007, 40, 105-109.	1.6	14
111	Non-A Hepatitis B Virus Genotypes in Antenatal Clinics, United Kingdom. Emerging Infectious Diseases, 2007, 13, 1689-1693.	2.0	6
112	Autochthonous hepatitis E in southwest England. Journal of Viral Hepatitis, 2007, 14, 304-309.	1.0	137
113	The role of hepatitis E virus testing in drugâ€induced liver injury. Alimentary Pharmacology and Therapeutics, 2007, 26, 1429-1435.	1.9	206
114	Characterization of hepatitis B surface antigen strains circulating in the Kingdom of Cambodia. Journal of Viral Hepatitis, 2006, 13, 62-66.	1.0	12
115	Transfusion-transmitted hepatitis E in a 'nonhyperendemic' country. Transfusion Medicine, 2006, 16, 79-83.	0.5	265
116	A low rate of hepatitis B virus vaccine breakthrough infections in Mongolia. Journal of Medical Virology, 2006, 78, 1554-1559.	2.5	12
117	European Multicenter Evaluation of High-Density DNA Probe Arrays for Detection of Hepatitis B Virus Resistance Mutations and Identification of Genotypes. Journal of Clinical Microbiology, 2006, 44, 2792-2800.	1.8	39
118	Indigenous hepatitis E virus infection in England and Wales. BMJ: British Medical Journal, 2006, 332, 1509.3-1510.	2.4	16
119	Non–Travelâ€Associated Hepatitis E in England and Wales: Demographic, Clinical, and Molecular Epidemiological Characteristics. Journal of Infectious Diseases, 2005, 192, 1166-1172.	1.9	220
120	HBV DNA levels and transmission of hepatitis B by health care workers. Journal of Clinical Virology, 2003, 27, 52-58.	1.6	48
121	Endocytosis of Hepatitis B Immune Globulin into Hepatocytes Inhibits the Secretion of Hepatitis B Virus Surface Antigen and Virions. Journal of Virology, 2003, 77, 8882-8892.	1.5	85
122	A †first loop' linear epitope accessible on native hepatitis B surface antigen that persists in the face of †second loop' immune escape. Journal of General Virology, 2003, 84, 269-275.	1.3	28
123	Comparison of commercial assays for the quantification of HBV DNA load in health care workers: calibration differences. Journal of Virological Methods, 2002, 100, 37-47.	1.0	33
124	Evidence for a dynamic host-parasite relationship in e-negative hepatitis B carriers. Journal of Medical Virology, 2002, 68, 505-512.	2.5	32
125	Novel immunoassay for the detection of hepatitis B surface ?escape? mutants and its application in liver transplant recipients. Journal of Medical Virology, 2001, 63, 210-216.	2.5	38
126	Detection of reverse transcriptase activity in the serum of patients with motor neurone disease. Journal of Medical Virology, 2000, 61, 527-532.	2.5	73

## SAMREEN IJAZ

#	Article	IF	CITATIONS
127	Secondary Attack Rates in Primary and Secondary School Bubbles Following a Confirmed Case: Active, Prospective National Surveillance, November to December 2020, England. SSRN Electronic Journal, 0, , .	0.4	2
128	Detection and Quantification of Antibody to SARS-CoV-2 Receptor Binding Domain Provides Enhanced Sensitivity, Specificity and Utility. SSRN Electronic Journal, 0, , .	0.4	3